8 November 2016
EMA/PDCO/674356/2016
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes for the meeting on 12-14 October 2016

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

12 October 2016, 08:30- 19:00, room 3A

13 October 2016, 08:30- 19:00, room 3A

14 October 2016, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes were adopted with amendments and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Isopropyl Alcohol / Chlorhexidine Gluconate - EMEA-002011-PIP01-16

GAMA Healthcare Ltd; Prevention of infections associated with transcutaneous procedures

Day 60 opinion

Dermatology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO recommends granting a waiver for Chlorhexidine Gluconate / Isopropyl Alcohol for all subsets of the paediatric population (0 to 18 years of age) in the condition of "Prevention of infections prior to invasive procedures", as the needs are already covered by a product with the same active substances and for an indication covered by the waived condition.

2.1.2. Naldemedine Tosylate - EMEA-001893-PIP01-15

Shionogi Limited; Opioid-induced constipation (OIC)

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee -the Committee agreed with this PIP EMEA-001893-PIP01-15 for naldemedine tosylate at their October 2016 meeting including a waiver and including a deferral.

2.1.3. Antithrombin alfa - EMEA-001154-PIP02-15

GTC Biotherapeutics UK Limited; Treatment of congenital antithrombin deficiency, Treatment of acquired antithrombin deficiency (Preeclampsia), Treatment of acquired antithrombin deficiency (ECMO) / Prophylaxis of peri-partum thromboembolic events in congenital antithrombin deficient patients., Antithrombin supplementation during ECMO procedure, Treatment of pregnant women less than 30 weeks GA with preeclampsia to prolong gestation and decrease foetal and neonatal morbidity and mortality.

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO adopted a negative opinion on the PIP application, by a written procedure, by consensus.

2.1.4. Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) - Orphan - EMEA-001886-PIP01-15

CSL Behring GmbH; Treatment of congenital Haemophilia A or B

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO discussed the PIP-application. The proposed development plan was deemed acceptable and a positive opinion was adopted.

2.1.5. Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) - Orphan - EMEA-001886-PIP02-15

CSL Behring GmbH; Treatment of congenital Factor VII Deficiency

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO discussed the applicant's proposal. The proposed development plan was deemed acceptable and a positive opinion was adopted.

2.1.6. Galcanezumab - EMEA-001860-PIP03-16

Eli Lilly and Company Limited; Prophylactic treatment of migraine headache

Day 120 opinion

Neurology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee following further information received by the applicant on outstanding points raised at D90, the PDCO agrees with the applicant's proposed PIP for galcanezumab for the condition prevention of migraine headaches including a waiver including a deferral at their October 2016 meeting.

2.1.7. inebilizumab - EMEA-001911-PIP01-15

MedImmune, LLC (a wholly owned subsidiary of AstraZeneca PLC); Treatment of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorders (NMOSD)

Day 120 opinion

Neurology

Summary of committee discussion:

The PDCO adopted a positive opinion.

2.1.8. EMEA-001978-PIP01-16

Actelion Registration Ltd.; Hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypertension.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should

not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.9. Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA - Orphan - EMEA-001993-PIP01-16

Quark Pharmaceuticals Inc.; Prevention of delayed graft function (DGF) after kidney transplantation / Prevention of DGF after transplantation of kidneys from deceased donors ≥ 45 years old

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee including contributions of external expert(s), the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for all subsets of the paediatric population (0 to less than 18 years of age) in the condition of prevention of delayed graft function (DGF) after kidney transplantation
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.10. Terguride hydrogenmaleate - Orphan - EMEA-002015-PIP01-16

medac Gesellschaft für klinische Spezialpräparate mbH; Treatment of Systemic scleroderma

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO view expressed at Day 30 was re-discussed and endorsed. The Committee does not support the waiver request.
The PDCO adopted a negative opinion.

2.1.11. Teprotumumab - EMEA-001973-PIP01-16

River Vision Development Corporation; Active thyroid eye disease

Day 60 opinion

Ophthalmology

Summary of committee discussion:

A positive opinion was adopted by the PDCO.

2.1.12. EMEA-001742-PIP02-16

Boehringer Ingelheim International GmbH; prevention of psychosis / prevention of first episode of psychosis (FEP) in individuals with attenuated psychotic syndrome (APS)

Day 60 opinion

Psychiatry

Summary of committee discussion:

The PDCO reviewed and endorsed the summary of the Day 30 discussion and concluded that the PIP proposal is not endorsable for the reasons detailed there.
The proposed PIP is therefore refused.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Hydrocortisone - EMEA-C-001283-PIP01-12

DIURNAL LIMITED; Treatment of adrenocortical insufficiency

Day 30 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The following completed studies were checked for compliance.
The PDCO adopted on 14 October 2016 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0031/2013) of 26 February 2013.

2.2.2. dupilumab - EMEA-C1-001501-PIP01-13-M03

Regeneron Pharmaceuticals, Inc.; Treatment of atopic dermatitis

Day 30 opinion

Dermatology

Summary of committee discussion:

The PDCO discussed the completed stud, and considered that this is compliant with the latest Agency's Decision (P/0219/2016) of 12 August 2016.
The PDCO finalised on 14-October-2016 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.3. eteplirsen - EMEA-C1-001722-PIP01-14-M01

Sarepta International C.V.; Treatment of Duchenne Muscular Dystrophy

Day 30 opinion

Neurology

Summary of committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0279/2016) of 07 October 2016.
The PDCO finalised on 14 October 2016 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.4. Adalimumab - EMEA-C-000366-PIP05-12-M02

AbbVie Ltd; Treatment of non-infectious uveitis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Ophthalmology / Dermatology / Gastroenterology-Hepatology

Summary of committee discussion:

The following completed studies was/were checked for compliance.
The PDCO adopted on 14-Oct-2016 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0200/2016) of 22 July 2016.

2.2.5. Benralizumab - EMEA-C1-001214-PIP01-11-M05

AstraZeneca AB; Treatment of asthma

Day 30 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed the completed studies which were subject of this partial compliance check and considered that these are compliant with the latest Agency's Decision (P/0213/2016) of 12 August 2016.
The following studies are deferred and must be checked for compliance in a later compliance procedure.
The PDCO finalised on 14 October 2016 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.6. Ivacaftor N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3- carboxamide / Lumacaftor 3 [6 ({[1 (2,2-difluoro 1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-3 methylpyridin-2-yl]benzoic acid - EMEA-C2-001582-PIP01-13

Vertex Pharmaceuticals (Europe) Limited; Treatment of cystic fibrosis

Day 60 opinion

Summary of committee discussion:

To conclude, the PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision P/0185/2015 of 24 August 2015.

The PDCO finalised on 14 October 2016 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.7. deferasirox - EMEA-C-001103-PIP01-10-M03

Novartis Europharm Limited; Treatment of chronic iron overload requiring chelation therapy

Day 0 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO took note of preceding procedures and reports on partially completed compliance (EMEA-C1-001103-PIP01-10, EMEA-C2-001103-PIP01-10, EMEA-C3-001103-PIP01-10-M01, EMEA-C4-001103-PIP01-10-M01, EMEA-C5-001103-PIP01-10-M03).
The PDCO adopted on 14 October 2016 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0175/2016) of 30 June 2016.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. ambrisentan - Orphan - EMEA-000434-PIP01-08-M04

Glaxo Group Limited; Treatment of Pulmonary Arterial Hypertension / Idiopathic (IPAH) and Familial (FPAH) Pulmonary Hypertension; Associated Pulmonary Hypertension (APAH)

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO re-discussed the modification request on 13 October 2016 also taking into account the clarification and the IDCM's minutes provided by the applicant after the D30 discussion and the further inputs received by the Formulation Working Group of the PDCO.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0267/2014 of 16/10/2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Dobutamine - EMEA-001262-PIP01-12-M02

Proveca Limited; Circulatory impairment / haemodynamic insufficiency

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be

accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0016/2013 of 25 January 2013)
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Empagliflozin - EMEA-000828-PIP01-09-M05

Boehringer Ingelheim International GmbH; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO adopted a favourable opinion on the modification of the agreed PIP.

2.3.4. linagliptin - EMEA-000498-PIP01-08-M06

Boehringer Ingelheim International GmbH; Type 2 Diabetes Mellitus / Type 2 Diabetes Mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO adopted a favourable opinion on the modification of the agreed PIP.

2.3.5. migalstat hydrochloride - Orphan - EMEA-001194-PIP01-11-M02

Amicus Therapeutics UK Ltd; Fabry disease

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0256/2014 of 01 October 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Semaglutide - EMEA-001441-PIP01-13-M01

Novo Nordisk A/S; Diabetes Mellitus type 2 / Treatment of Diabetes Mellitus type 2

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0095/2015 of 08/05/2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Ceftobiprole medocaril (sodium) - EMEA-000205-PIP02-11-M02

Basilea Pharmaceutica International Ltd.; J15: Bacterial pneumoniae no elsewhere classified, J13: Pneumonia due to Streptococcus pneumoniae, J14: Pneumonia due to Hemophilus influenzae / Treatment of nosocomial pneumonia, Treatment of community acquired pneumonia

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO's view expressed on Day 30 was re-discussed and endorsed.
In summary, based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0083/2014 of 4 April 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. daclatasvir - EMEA-001191-PIP01-11-M02

Bristol-Myers Squibb Pharma EEIG; Treatment of chronic viral hepatitis C / Daklinza is indicated in combination with sofosbuvir (SOF) for the treatment of CHC in children 3 years of age and older, and adolescents.

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the above discussion of the additional justifications submitted by the applicant and a review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could thus be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0180/2014 of 17 July 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Eravacycline - EMEA-001555-PIP01-13-M02

Tetraphase Pharmaceuticals, Inc.; Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infection / Complicated Intra-Abdominal Infection, Urinary Tract Infection

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0046/2015 of 06 March 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Telavancin hydrochloride - EMEA-000239-PIP01-08-M02

Clinigen Healthcare Ltd; Nosocomial Pneumonia (NP), Complicated skin and soft tissue infections (cSSTI) / Waiver, Nosocomial Pneumonia (NP)

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0111/2015 of 5/6/2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Tenofovir alafenamide / Emtricitabine / Bictegravir - EMEA-001766-PIP01-15-M01

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection / Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0316/2015 of 21 December 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. tenofovir disoproxil / emtricitabine / cobicistat / elvitegravir - EMEA-000970-PIP01-10-M01

Gilead Sciences International Ltd; B23 Human immunodeficiency virus disease [HIV] resulting in other conditions / Stribild indicated for the treatment of HIV-1 infection in paediatric patients aged 12 years and over.

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

At their October 2016 meeting the PDCO discussed the responses received by the applicant

following the D30 discussion and agreed with the modification proposed on the PIP.

2.3.13. Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA - Orphan - EMEA-001244-PIP01-11-M01

bluebird bio France; Treatment of adrenoleukodystrophy

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO discussed the Request for Modification of an agreed PIP. Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0119/2013 of 3 May 2013). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M03

GW Pharma Ltd; Spasticity / Intractable spasticity due to cerebral palsy or traumatic CNS injury

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO reviewed the application including the new information submitted after Day 30. The PDCO, as explained above, adopted nevertheless a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Perampanel - EMEA-000467-PIP01-08-M08

Eisai Europe Limited; Treatment of treatment-resistant epilepsies / Adjunctive therapy in patients with other paediatric epilepsies, Adjunctive therapy in patients with refractory partial onset seizures including secondarily generalised seizures.

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0118/2016 of 22 April 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 - Orphan - EMEA-001654-PIP01-14-M01

Novartis Europharm Limited; B cell acute lymphoblastic leukaemia (ALL) / Treatment of B cell acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed after at least two prior regimens or are refractory

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Bosutinib - Orphan - EMEA-000727-PIP01-09-M02

Pfizer Limited; CML / Treatment of CML in children and adolescents (from 1 to <18 years of age) with resistance or intolerance to prior TKI therapy.

Day 60 opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The draft Opinion was shared with the applicant before the D60 discussion. .
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0016/2016 of 29/01/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Eribulin - EMEA-001261-PIP01-11-M03

Eisai Europe Ltd; Soft Tissue Sarcoma / Treatment of non-Rhabdomyosarcoma soft tissue sarcoma, Treatment of Rhabdomyosarcoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed the request for modification of the PIP agreed for eribulin on 13 October 2016, taking into account comments on the draft Opinion by the applicant.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set

in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.19. pixantrone - EMEA-000713-PIP02-10-M04

CTI Life Sciences Limited; ICD-09. C83 Diffuse Non-Hodgkin's Lymphoma (including C83.7 Burkitt Lymphoma, C83.5 Lymphoblastic Lymphoma, C83.3 Large-cell Lymphoma) / Treatment of Non-Hodgkin's Lymphoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed on 13 October 2016 the modification request for the PIP agreed for pixantrone taking into account the supplementary information received from the applicant. Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.20. Sunitinib - EMEA-000342-PIP01-08-M05

Pfizer Limited; CD10 code C49.4 malignant neoplasms of connective and soft tissue of abdomen - gastro-intestinal stromal tumours (GIST) / Treatment of gastro-intestinal stromal tumour in paediatric patients aged 6 to less than 18

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO discussed on 13 October 20016 the proposed modifications of the PIP agreed for sunitinib, taking into account the supplementary information by the applicant and the discussion with the CHMP Rapporteur.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.21. Inotuzumab ozogamicin - Orphan - EMEA-001429-PIP01-13-M01

Pfizer Limited; Treatment of Acute Lympohoblastic Leukaemia / For the treatment of relapsed or refractory B cell precursor Acute Lympohoblastic Leukaemia

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.22. Bupropion HCl / Naltrexone HCl - EMEA-001373-PIP01-12-M02

Orexigen Therapeutics Ireland Limited; Treatment of obesity / Treatment of obesity

Day 60 opinion

Other

Summary of committee discussion:

In conclusion, the PDCO adopted a positive opinion.

2.3.23. fentanyl hydrocholoride - EMEA-001509-PIP01-13-M01

Incline Therapeutics Europe Ltd. (a wholly owned subsidiary of The Medicines Company); Treatment of acute pain

Day 60 opinion

Pain

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.24. methoxyflurane - EMEA-000334-PIP01-08-M05

Medical Developments UK Ltd; treatment of acute pain / 1. Self administration to conscious patients with minor trauma and associated pain, under supervision of personnel trained in its use 2. For the management of acute pain associated with short surgical procedures, such as the change of dressings, dislocations and injections

Day 60 opinion

Pain

Summary of committee discussion:

The PDCO re-discussed the application including the additional information received after Day 30.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.25. Tapentadol - EMEA-000018-PIP01-07-M12

Grünenthal GmbH; Acute pain / Treatment of acute pain

Day 60 opinion

Pain

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.26. Tapentadol - EMEA-000325-PIP01-08-M06

Grünenthal GmbH; Chronic pain / Treatment of chronic pain

Day 60 opinion

Pain

Summary of committee discussion:

While the committee might consider some of the proposed changes agreeable, they have not been sufficiently substantiated and justified to allow the committee to conclude. As a consequence, the PDCO has adopted a negative opinion.
The details of the previously agreed PIP remain unchanged.

2.3.27. Loxapine - EMEA-001115-PIP01-10-M05

Ferrer Internacional, S.A.; Bipolar disorder, Schizophrenia / For rapid control of agitation in patients with schizophrenia, For rapid control of agitation in patients with bipolar disorder

Day 60 opinion

Psychiatry

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

No items.

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Eculizumab - Orphan - EMEA-000876-PIP03-14

Alexion Europe SAS; Neuromyelitis Optica Spectrum Disorders / Treatment of Relapsing Neuromyelitis Optica Spectrum Disorders in the paediatric population

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.2. Octenidine dihydrochloride - Orphan - EMEA-001384-PIP01-12

Schülke & Mayr GmbH; Skin disinfection

Day 90 discussion

Neonatology - Paediatric Intensive Care

3.1.3. synthetic surfactant protein B analogue / synthetic surfactant protein C analogue / 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol sodium salt / dipalmitoylphosphatidylcholine - Orphan - EMEA-001780-PIP01-15

Chiesi Farmaceutici SpA; treatment of respiratory distress syndrome (RDS) / treatment of respiratory distress syndrome (RDS) in preterm neonates of less than 37 weeks of gestational age

Day 90 discussion

Neonatology - Paediatric Intensive Care

3.1.4. Galcanezumab - EMEA-001860-PIP04-16

Prophylactic treatment of cluster headache

Day 90 discussion

Neurology

3.1.5. Dexamethasone / Povidone-Iodine - EMEA-001936-PIP01-16

Treatment of Infectious conjunctivitis (adenoviral and bacterial)

Day 90 discussion

Ophthalmology

3.1.6. Macimorelin - EMEA-001988-PIP01-16

Growth hormone deficiency / Diagnosis of growth hormone deficiency

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Diagnostic

3.1.7. (2R,3S)-2-(4-Cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide - Orphan - EMEA-002023-PIP01-16

ChemoCentryx, Ltd.; Treatment of ANCA-associated vasculitis

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.8. Atacicept - EMEA-002004-PIP01-16

Treatment of systemic lupus erythematosus

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.9. Recombinant humanised monoclonal antibody against human complement component C5a - EMEA-002009-PIP01-16

Treatment of acute Graft-versus-Host Disease

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.10. Edasalonexent [N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide] - Orphan - EMEA-001960-PIP02-16

Catabasis Pharmaceuticals Inc.; Duchenne Muscular Dystrophy / Treatment of Duchenne Muscular Dystrophy

Day 60 discussion

Neurology

3.1.11. Daunorubicin (liposomal combination) / Cytarabine (liposomal combination) - Orphan - EMEA-001858-PIP02-16

Jazz Pharmaceuticals Ireland Limited; Acute myeloid leukemia / Treatment

Day 60 discussion

Oncology

3.1.12. lenadogene nolparvovec - Orphan - EMEA-001992-PIP02-16

GENSIGHT-BIOLOGICS; Leber Hereditary Optic Neuropathy (LHON)

Day 60 discussion

Ophthalmology

3.1.13. Mexiletine hydrochloride - Orphan - EMEA-002012-PIP01-16

Lupin (Europe) Ltd.; Treatment of myotonic disorders / Symptomatic treatment of myotonic disorders

Day 60 discussion

Other

3.1.14. Betrixaban - EMEA-001834-PIP02-16

Prevention of venous thromboembolism / Adults and children

Day 30 discussion

Cardiovascular Diseases

3.1.15. lauromacrogol 400 - EMEA-002026-PIP02-16

venous therapeutic procedures / sclerotherapy of varicose veins

Day 30 discussion

Cardiovascular Diseases

3.1.16. Botulinum toxin, Type A - EMEA-002038-PIP01-16

Treatment of glabellar lines

Day 30 discussion

Dermatology

3.1.17. rAAV8-hUGT1A1 - Orphan - EMEA-002021-PIP01-16

GENETHON; Treatment of Crigler-Najjar syndrome / Treatment of Severe Crigler-Najjar syndrome requiring phototherapy

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.18. Filgotinib - EMEA-001619-PIP03-16

Ulcerative colitis (UC), Crohn's disease (CD) / Treatment of paediatric patients 2 years of age and older with moderately-to-severely active ulcerative colitis, Treatment of paediatric patients 2 years of age and older with moderately-to-severely active Crohn's disease

Day 30 discussion

Gastroenterology-Hepatology

3.1.19. Peramivir - EMEA-001856-PIP02-16

Treatment of influenza / Treatment of influenza

Day 30 discussion

Infectious Diseases

3.1.20. Methyl 3-((2R)-2-hydroxy-4-(((((S)-1-methoxy-1-oxopropan-2-yl) amino)(phenoxy)phosphoryl)oxy)-3,3-dimethylbutanamido)propanoate - Orphan - EMEA-002036-PIP01-16

Retrophin Europe Limited; Treatment of Pantothenate Kinase Associated Neurodegeneration (PKAN)

Day 30 discussion

Neurology

3.1.21. Sarizotan hydrochloride - Orphan - EMEA-001808-PIP02-16

Newron Pharmaceuticals SpA; Treatment of Rett syndrome

Day 30 discussion

Neurology

3.1.22. nintedanib - Orphan - EMEA-001006-PIP03-16

Boehringer Ingelheim International GmbH; Treatment of lung carcinoma (small cell and non-small cell carcinoma), Treatment of mesothelioma

Day 30 discussion

Oncology

3.1.23. vemurafenib - EMEA-000978-PIP03-16

Treatment of histiocytic disease

Day 30 discussion

Oncology

3.1.24. Netarsudil - EMEA-002037-PIP01-16

Open Angle Glaucoma / Ocular Hypertension

Day 30 discussion

Ophthalmology

3.1.25. Entolimod - Orphan - EMEA-002020-PIP01-16

Cleveland BioLabs Inc; Treatment of acute Radiation Syndrome / Entolimod is indicated for reducing the risk of death following exposure to potentially lethal irradiation occurring as the results of a radiation disaster

Day 30 discussion

Other

3.1.26. palonosetron / fosnetupitant (netupitant prodrug) - EMEA-001198-PIP02-16

Chemotherapy-Induced Nausea and Vomiting

Day 30 discussion

Other

3.1.27. Ibuprofen - EMEA-002017-PIP01-16

Treatment of pain, Treatment of febrile disorders / Treatment of pain of non-serious arthritic conditions, Treatment of backache, Treatment of dental pain, Treatment of neuralgia, Treatment of headache, Treatment of rheumatic or muscular pain, Treatment of migraine, Treatment of dysmenorrhoea, Treatment of fever

Day 30 discussion

Other / Pain

3.1.28. pimavanserin - EMEA-001688-PIP03-16

Treatment of schizophrenia and other psychotic disorders

Day 30 discussion

Psychiatry

3.1.29. DNA plasmid encoding HPV type 18 consensus E6 and E7 proteins (pGX3002) / DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX3001) - EMEA-002022-PIP01-16

Treatment of high grade squamous intraepithelial lesions (HSIL) of the cervix caused by HPV types 16 and 18

Day 30 discussion

Vaccines / Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Gemtuzumab linked to Ozogamicin - EMEA-C1-001733-PIP02-15

Pfizer Limited; Treatment of acute myeloid leukaemia

Day 30 discussion

Oncology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. sacubitril / valsartan - EMEA-000316-PIP02-11-M03

Novartis Europharm Ltd.; Heart failure / Treatment of heart failure

Day 30 discussion

Cardiovascular Diseases

3.3.2. Allantoin - Orphan - EMEA-001590-PIP01-13-M03

Scioderm, Inc.; Treatment of epidermolysis bullosa

Day 30 discussion

Dermatology

3.3.3. Liquid extract ethanolic 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M01

Legacy Healthcare; Treatment of alopecia

Day 30 discussion

Dermatology

3.3.4. Rubidium Rb-82 Chloride - EMEA-000882-PIP03-11-M02

Jubilant DraxImage Inc.; Visualization of myocardial perfusion for diagnostic purposes

Day 30 discussion

Diagnostic

3.3.5. Estetrol & Drospirenone - EMEA-001332-PIP01-12-M02

Estetra SPRL; Prevention of pregnancy

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. deferiprone - Orphan - EMEA-001126-PIP01-10-M02

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) - Coordinator for DEEP Project

(HEALTH-F4-2010-261483); treatment of chronic iron overload requiring chelation therapy / treatment of iron overload in paediatric patients affected by haemoglobinopathies requiring chronic transfusions and iron chelation

Day 30 discussion

Haematology-Hemostaseology

3.3.7. Ceftaroline fosamil (established INN) - EMEA-000769-PIP01-09-M06

AstraZeneca AB; Treatment of cSSTI (complicated skin and soft tissue infections), Treatment of CAP (community-aquired pneumonia) / Treatment of cSSTI (complicated skin and soft tissue infections), Treatment of CAP (community-aquired pneumonia)

Day 30 discussion

Infectious Diseases

3.3.8. Talimogene laherparepvec - EMEA-001251-PIP01-11-M02

Amgen Europe B.V.; Treatment of solid malignant non-CNS tumours

Day 30 discussion

Oncology

3.3.9. Finerenone - EMEA-001623-PIP01-14-M01

Bayer Pharma AG; Chronic Kidney Disease / Treatment of chronic kidney disease associated with proteinuria in addition to a therapy with ACEi or ARB

Day 30 discussion

Uro-nephrology

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 3 January 2017 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

4.3.1. Nomination of PDCO members for task force to work on Respiratory Drafting Group (RDG) letter to CHMP and PDCO 'Request for advice on how to address issues related to therapeutic equivalence for orally inhaled products for children'

Summary of committee discussion:

Two PDCO members, Eva Agurell (pdco@mpa.se) and Jorrit Gerritsen (j.gerritsen@umcg.nl), volunteered to participate in this activity.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1.1. PDCO-SAWP interaction training session for PDCO members

Summary of committee discussion:

- PDCO members were reminded about their responsibility to contribute to Paediatric scientific advice applications. They were provided with an update on when and how to provide input.
- The Best Practice Guide on SAWP-PDCO interactions is included in MMD.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. DNA plasmids encoding for HPV type 16 or 18 consensus E6 and E7 antigens - EMEA-28-2016

Inovio Pharmaceuticals Inc.; All classes of medicinal products for treatment of vulvar intraepithelial neoplasia/ Treatment of high grade squamous intraepithelial lesions (HSIL) of the vulva caused by HPV types 16 and 18

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: none currently identified.

6.1.2. Tremelimumab - EMEA-29-2016

AstraZeneca AB; Treatment of lung carcinoma (small cell and non-small cell carcinoma)/ 1) Tremelimumab in combination with durvalumab is indicated for the 1st line treatment of patients with locally advanced or metastatic NSCLC with tumours with no sensitizing EGFR mutation or ALK translocation; 2) Tremelimumab in combination with durvalumab is indicated for the treatment of patients with locally advanced or metastatic NSCLC which has progressed on or after platinum-based chemotherapy

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/1/2011 to the planned therapeutic indications was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: paediatric solid malignant tumours, malignant neoplasms of lymphoid tissue.

Note: in case of removal from the list of class waivers listed in the Agency's Decision CW/1/2011, the requirements set out in Article 7 and 8 of Regulation (EC) No 1901/2006 of the Agency's Decision CW/0001/2015 shall apply after 36 months from the date of the removal from the list of class waivers

6.1.3. Tremelimumab - EMEA-30-2016

AstraZeneca AB; Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma (excluding nasopharyngeal carcinoma or lympho-epithelioma) 1) Tremelimumab in combination with durvalumab is indicated for the 2nd line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck, progressed during or after treatment with 1 platinum-based regimen; 2) Tremelimumab in combination with durvalumab is indicated for the 1st line treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/1/2011 to the planned therapeutic indications was confirmed.

Other potential paediatric interest of this medicine suggested by PDCO: paediatric solid malignant tumours, malignant neoplasms of lymphoid tissue.

Note: in case of removal from the list of class waivers listed in the Agency's Decision CW/1/2011, the requirements set out in Article 7 and 8 of Regulation (EC) No 1901/2006 of the Agency's Decision CW/0001/2015 shall apply after 36 months from the date of the removal from the list of class waivers

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Macitentan - EMEA-001032-PIP01-10-M02

Actelion Registration Ltd.; Treatment of idiopathic pulmonary fibrosis Treatment of pulmonary arterial hypertension/ Treatment of systemic sclerosis/Treatment of Eisenmenger's syndrome

Summary of committee discussion:

The PDCO has reviewed your request during the plenary meeting held on 12-14 October 2016. The PDCO is of the view that the proposed indication “treatment of Eisenmenger's syndrome”, falls under the scope of the above mentioned Decision, as the indication is considered to be covered by the condition “Treatment of pulmonary arterial hypertension” listed in the Agency Decision.

8. Annual reports on deferrals

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Outline for Agenda of PDCO November 2016 meeting

PDCO Chair: Dirk Mentzer

Summary of committee discussion:

The PDCO took note of the proposed outline for the Agenda of the PDCO November 2016 meeting.

9.1.2. Preparations for elections of PDCO Vice-chair

Summary of committee discussion:

PDCO members were reminded that Koenraad Norga has served as vice-chair of the PDCO since November 2013 and his current term of office will shortly come to an end. In preparation for the vice-chair election to be conducted at the November 2016 PDCO meeting the members were reminded of the election procedure. PDCO eligible members were invited to indicate their interest in standing for this position before the November 2016 plenary meeting.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about 2 medicinal products, Chenodeoxycholic acid sigma-tau and NovoRapid for which the CHMP adopted a positive opinion recommending paediatric indication during their meeting in September 2016.

9.2.2. Report on CHMP approach for Extrapolation in Juvenile Idiopathic Arthritis (JIA), Inflammatory bowel disease (IBD) and Psoriasis

Summary of committee discussion:

The PDCO members were informed about the experience gathered, so far, with products in the field of JIA, IBDs and psoriasis having undergone CHMP discussion. The use of paediatric data was presented as well as the requirements to allow for paediatric indications.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Summary of committee discussion:

The chair of the NcWG identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Report on the updated Paediatric Addendum to the guideline on acute heart failure (AHF)

Summary of committee discussion:

The PDCO members were presented the changes to the Paediatric Addendum to the guideline on clinical investigation of medicinal products in the treatment of acute heart failure implemented after the GCG discussion. The Committee was informed about the pending adoption of the Paediatric Addendum by the CHMP.

9.4. Cooperation within the EU regulatory network

9.4.1. European Commission (EC) 10-year report on Paediatric Regulation

Summary of committee discussion:

The PDCO members were updated on the status of the 10-year report on Paediatric Regulation.

9.4.2. Questions of the PDCO for the Enpr-EMA networks to be invited at the November PDCO

PDCO member: Angelika Siapkara

Summary of committee discussion:

The EMA proposed some questions to be addressed by the EnprEMA members when presenting at the PDCO meeting in November 2016. The PDCO recommended some refinement to orientate the discussion on scenarios for mutual exchange of information and cooperation.

9.5. Cooperation with International Regulators

9.5.1. Collaboration with FDA

Summary of committee discussion:

The Committee was informed that the Agenda of the weekly Pediatric Review Committee (PeRC) of the FDA will be made available in advance to the Paediatric Medicines Office at EMA and to all PDCO members. Remote participation to PeRC meetings via teleconference will be possible, for the PDCO members and the EMA Paediatric Coordinators. PDCO members will also receive the Pedsclips Paediatric Clinical Pharmacology Newsletter, prepared by the Office of Clinical Pharmacology, CDER, FDA.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

9.7.1. PDCO Work Plan 2017

Summary of committee discussion:

The committee discussed the work plan and brought ideas to the content of the document. The updated document will be circulated for comments in preparation of further discussion at the November 2016 PDCO meeting.

9.8. Planning and reporting

None

10. Any other business

10.1.1. Discussion on study design/endpoints in Pulmonary Arterial Hypertension (PAH)

Summary of committee discussion:

The outcome of the PAH TC was presented to PDCO in view to explore the different scenario as next steps.

10.1.2. Report on Workshop on extrapolation of efficacy and safety in medicine development across age groups

Summary of committee discussion:

The report was presented to PDCO and CHMP. The report will be available on the EMA website.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The participants discussed the upcoming public meetings and prepared a product-related discussion.

11.1.2. Neonatology

Summary of committee discussion:

The participants discussed issues related to the neonatal guideline.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 12-19 October 2016 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting on:	EMEA-000434-PIP01-08-M04
Jacqueline Carleer	Alternate	Belgium	No interests declared	
Vessela Boudinova	Alternate	Bulgaria	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No participation in discussion, final deliberations and voting on:	EMEA-000978-PIP03-16
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Ann Marie Kaukonen	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Carola de Beaufort *via*	Member	Luxembourg	No restrictions	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
TC	(CHMP alternate)		applicable to this meeting	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Jolanta Witkowska-Ożogowska	Alternate	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Riccardo Riccardi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jorrit Gerritsen	Alternate	Healthcare Professionals' Representative	No interests declared	
Paolo Paolucci	Alternate	Healthcare Professionals' Representative	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Günther Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Tsvetana Schyns-Liharska	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Juliana Min	Expert - in person*	United Kingdom	No restrictions applicable to this meeting	
Sara Homer	Expert - in person*		No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Shiva Ramroop	Expert - in person*	United Kingdom	No restrictions applicable to this meeting	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases.
Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers,
see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/